Earnings call transcript: Elite Pharma's Q3 2024 revenue dips 8%, stock falls 9.96%
Elite Pharmaceuticals, with a market capitalization of $531 million, reported a decline in third-quarter revenue for 2024, falling 8% from the previous year. Despite a strong nine-month performance, ...
Why Recursion Pharmaceuticals Stock Is Soaring Today
Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
BioSpace8d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Benzinga.com15d
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief
Now Read: Purdue Pharma, Sackler Family To Pay $7.4 Billion In Settlement Over OxyContin That Fueled ‘Devastating’ Opioid Epidemic Government surveys show analgesics, or medications that ...
BioSpace15d
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Business Insider15d
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
This anticipated adoption, along with a projected modest market penetration, underpins the increased price target for Vertex Pharmaceuticals’ stock, contributing to Fein’s Buy rating.
The Indianapolis Star15d
Indiana basketball vs Purdue final score: Boilermakers beat Hoosiers at Mackey Arena
The Purdue and Indiana men's basketball teams faced off on Friday night with the Boilermakers coming away with an 81-76 win at Mackey Arena. There were 15 lead changes. Purdue wins No. 17 for the ...
Eagle-Tribune16d
Our View: Sacklers owe more than money for the opioid crisis
The recent settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is a welcome ...
ETF Daily News18d
Universe Pharmaceuticals (NYSE:UPC) Stock Price Down 0.2% – Should You Sell?
The stock had previously closed at $0.50. A hedge fund recently bought a new stake in Universe Pharmaceuticals stock. MML Investors Services LLC acquired a new position in Universe Pharmaceuticals ...
Seeking Alpha19d
GHC Graham Holdings Company
and non-academic operations support services to the Purdue University Global; operations support services for online courses and programs; training and test preparation services for accounting and ...
The Norman Transcript20d
Purdue Pharma and owners to pay $7.4 billion in settlement to lawsuits over the toll of OxyContin
Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription ...